Back to top

Analyst Blog

Zacks Equity Research

Perrigo Seeks Generic Approval

TEVA PRGO

 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Perrigo Company (PRGO - Analyst Report) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA), seeking approval for its generic version of Teva Pharmaceutical Industries Limited’s (TEVA - Analyst Report) ProAir HFA inhaler. The application included contributions from Perrigo’s partner on the project, the privately-held Catalent Pharma.

ProAir is marketed for treating and preventing bronchospasm symptoms in patients aged 4 years and above. As per data released by Wolters Kluwer Health, annual sales of the inhaler were approximately $1.07 billion.

We note that Teva has already challenged Perrigo’s application, thereby initiating the litigation process under the Hatch-Waxman Act.  Perrigo stated in its press release that it is the first company to seek approval for the generic version of the drug and is therefore entitled to 180 days of generic exclusivity.

We note that the generic segment at Perrigo (Rx Pharmaceuticals) performed exceptionally well in fiscal 2012 (ended June 30, 2012) with sales climbing 80% year over year to $274 million. The generic unit has seen quite a few approvals over the past few months including its generic versions of Clobex shampoo, inflammatory acne therapy Duac gel, hyperphosphatemia drug, Phoslo Gelcaps and vaginal cream Gynazole 1 for the local treatment of vulvovaginal candidiasis.

Our Recommendation

Earlier in the month, we downgraded Perrigo to Neutral from Outperform following the disappointing revenue numbers reported by the company in the fourth quarter of fiscal 2012.

Perrigo’s fourth quarter fiscal 2012 revenues of $832 million fell short of the Zacks Consensus Estimate of $854 million, primarily due to weakness in the Consumer HealthCare segment. The stock carries a Zacks #3 Rank (Hold rating) in the short run.
 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.33 +14.82%
ANI PHARMACE ANIP 24.79 +14.66%
E HOUSECHINA EJ 10.99 +9.24%
CANADIAN SOL CSIQ 26.97 +7.15%
INTERNATIONA ICAGY 33.30 +5.38%